Small target for melanoma eradication gets big results

Share this content:

Immune cells targeting just two cancer-related proteins in melanoma cells largely shrunk the tumors and kept the melanoma at bay for more than 36 weeks post-injection.

As explained by researchers from Germany's University of Cologne, current cancer-therapy regimens attempt to eliminate all malignant cells of a tumor lesion. This goal is based on an assumption that all cancer cells have equal malignant capacities. To show that selective elimination of a definite, minor tumor cell subpopulation can effectively combat melanoma lesions—which often produce tumors that contain generically diverse types of cells—the researchers targeted a tumor cell subset in human melanomas grafted into mice.

Although the two targeted proteins decorate the surfaces of fewer than 2% of melanoma cells in typical lesions, the immunotherapy strategy “lastingly eradicated melanoma lesions, whereas targeting of any random 10% tumor cell subset was not effective,” noted the investigators in Proceedings of the National Academy of Sciences (2011;108[6]:2474-2479). “Our data challenge the biological therapy and current drug development paradigms in the treatment of cancer.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs